{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:02:56Z","timestamp":1790370176233,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bulcan.2026.07.005","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:32:34Z","timestamp":1790368354000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["La radioth\u00e9rapie interne vectoris\u00e9e\u00a0: avanc\u00e9es, progr\u00e8s et perspectives"],"prefix":"10.1016","author":[{"given":"Lavinia","family":"Vija","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9deric","family":"Courbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.07.005_bib0205","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617\u00a0for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0210","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617\u00a0plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3\u00a0trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0215","unstructured":"ESMO 2025: final analysis of patients treated with 177Lu-PSMA-617\u00a0in early access program in mCRPC in France. https:\/\/www.urotoday.com\/conference-highlights\/esmo-2025\/esmo-2025-prostate-cancer\/164169-esmo-2025-final-analysis-of-patients-treated-with-177lu-psma-617-in-early-access-program-in-mcrpc-in-france.html."},{"key":"10.1016\/j.bulcan.2026.07.005_bib0220","first-page":"169","article-title":"\u00c9tude capacit\u00e9 th\u00e9ranostique 2023\u20132024\u00a0\u2013\u00a0mod\u00e9lisation sur la base de la RIV-PSMA. Radioth\u00e9rapie interne vectoris\u00e9e (RIV), une approche th\u00e9ranostique \u00e0 laquelle le patient doit avoir acc\u00e8s. Partie I\u00a0: consolidation nationale","volume":"48","author":"Giraudet","year":"2024","journal-title":"Med Nucl"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0225","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"A randomised controlled phase 3\u00a0trial of lutetium-177-PSMA-617\u00a0in taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore)","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0230","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617\u00a0plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2\u00a0trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0235","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","article-title":"Enzalutamide plus radium-223\u00a0in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3\u00a0trial","volume":"36","author":"Tombal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0240","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617\u00a0and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2\u00a0study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0245","doi-asserted-by":"crossref","unstructured":"Scott T. Tagawa. ESMO 2025: Phase III Trial of [177Lu]Lu-PSMA-617\u00a0Combined with ADT\u00a0+\u00a0ARPI in Patients with PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer (PSMAddition). 2025.","DOI":"10.1016\/j.annonc.2025.09.101"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0250","unstructured":"Why we did what we did: PSMA PET\/CT selection criteria for the VISION trial\u00a0\u2013\u00a0PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/35086895\/."},{"key":"10.1016\/j.bulcan.2026.07.005_bib0255","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0260","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE\u00a0V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0265","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.2967\/jnumed.122.265242","article-title":"PSMA PET tumor-to-salivary gland ratio to predict response to [177Lu]PSMA radioligand therapy: an international multicenter retrospective study","volume":"64","author":"Hotta","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0270","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0275","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0280","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO-25-02834","article-title":"Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4","volume":"44","author":"Armstrong","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0285","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2967\/jnumed.124.269252","article-title":"Clinical trial protocol for LuCAB: a phase I\u2013II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617\u00a0in patients with metastatic castration-resistant prostate cancer","volume":"66","author":"Kostos","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0290","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617\u00a0followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1\u00a0trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0295","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2967\/jnumed.125.269495","article-title":"Randomized phase 2\u00a0trial of an extended and flexible dosing schedule of 177Lu-PSMA molecular radiotherapy in patients with metastatic castration-resistant prostate cancer (FLEX-MRT): study protocol","volume":"66","author":"Holzgreve","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0300","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1016\/j.ijrobp.2024.07.1254","article-title":"Phase 2\u00a0prospective trial of re-treatment with177\u00a0lu-PSMA-617\u00a0molecular radiotherapy for metastatic castration resistant prostate cancer (RE-LuPSMA): study protocol","volume":"120","author":"Nikitas","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0305","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3\u00a0trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0310","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3\u00a0trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0315","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0320","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(26)00604-5","article-title":"[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial","volume":"408","author":"Walter","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0325","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(26)00108-7","article-title":"[177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2\u00a0trial","volume":"27","author":"Baudin","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0335","doi-asserted-by":"crossref","first-page":"S960","DOI":"10.1016\/j.annonc.2022.07.1028","article-title":"902TiP COMPOSE: pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2\u00a0and grade 3\u00a0gastroenteropancreatic neuroendocrine tumours","volume":"33","author":"Halfdanarson","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0340","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2025.43.4_suppl.661","article-title":"Phase 1b portion of the ACTION-1 phase 1b\/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: safety and efficacy findings","volume":"43","author":"Strosberg","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0345","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025\u00a0American Thyroid Association Management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0350","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S2213-8587(25)00064-6","article-title":"Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement","volume":"13","author":"Leboulleux","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0355","unstructured":"Web I. Abstracts\u00a0\u2013\u00a017th International Thyroid Congress. https:\/\/itc2025.com\/evento\/itc2025\/trabalhosaprovados\/naintegra\/1112402."},{"key":"10.1016\/j.bulcan.2026.07.005_bib0360","doi-asserted-by":"crossref","first-page":"e14358","DOI":"10.1111\/eci.14358","article-title":"[225Ac]Ac-PSMA for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"55","author":"Garo","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0365","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","article-title":"First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta\u00a0\u2013\u00a0Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1\/2\u00a0study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0370","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/ph17030334","article-title":"Towards effective targeted alpha therapy for neuroendocrine tumours: a review","volume":"17","author":"Gape","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0375","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00259-021-05474-1","article-title":"Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity","volume":"49","author":"Kratochwil","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0380","doi-asserted-by":"crossref","first-page":"S630","DOI":"10.1016\/j.annonc.2025.08.1601","volume":"36","author":"Strosberg","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0385","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.125.270810","article-title":"First-in-human study of [211At]NaAt as targeted (-therapy in patients with radioiodine-refractory thyroid cancer (Alpha-T1\u00a0trial)","volume":"66","author":"Watabe","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0390","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.3390\/ijms23169434","article-title":"Comparison of the therapeutic effects of [211At]NaAt and [131I]NaI in an NIS-expressing thyroid cancer mouse model","volume":"23","author":"Watabe","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0395","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2967\/jnumed.124.269378","article-title":"Rethinking dosimetry: a European perspective","volume":"66","author":"Tran-Gia","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bulcan.2026.07.005_bib0200","first-page":"124","article-title":"Radioth\u00e9rapie interne vectoris\u00e9e et th\u00e9ranostique en France\u202f: recommandations de bonnes pratiques par la Soci\u00e9t\u00e9 fran\u00e7aise de m\u00e9decine nucl\u00e9aire","volume":"50","author":"Bailly","year":"2026","journal-title":"Med Nucl"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512600398X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512600398X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:32:40Z","timestamp":1790368360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512600398X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S000745512600398X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La radioth\u00e9rapie interne vectoris\u00e9e\u00a0: avanc\u00e9es, progr\u00e8s et perspectives","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}